Through cbioportal (http://www.cbioportal.org/) analysis of 186 TCGA pancreatic cancer specimens, we found that patients with high expression of GLI2 and SOX2 in the tumor had ~70% chance of cancer relapse following gemcitabine treatment. The gene discussed is GLI2; the disease is neoplasm.